A nanocarrier based on a genetically engineered protein cage to deliver doxorubicin to human hepatocellular carcinoma cells
A nanocarrier based on a genetically engineered protein cage to deliver doxorubicin to human hepatocellular carcinoma cells
复制标题
DOI：
10.1039/c3cc44508a
复制
发表时间：
2013-01-01
影响因子：
4.9
通讯作者：
Hashizume, Makoto
中科院分区：
文献类型：
--
作者：
Toita, Riki;Murata, Masaharu;Hashizume, Makoto
在这里，我们报道了基因工程蛋白笼(HspG41C-SP94)的制备，它被人肝细胞癌(HCC)细胞选择性地摄取。工程蛋白CAGE-阿霉素(DOX)结合物对肝癌细胞具有与游离DOX相同的细胞毒性，但对正常肝细胞的细胞毒性要小得多。
Herein, we report the preparation of genetically engineered protein cages (HspG41C-SP94), taken up selectively by human hepatocellular carcinoma (HCC) cells. An engineered protein cage-doxorubicin (DOX) conjugate was as cytotoxic as free DOX against HCC cells but much less cytotoxic against normal hepatocytes.